Raising awareness about head and neck cancer through the Make Sense campaign

Cancer care in developing countries

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Young oncologists bridging the gap between translational and clinical cancer research

Questions raised about the future of lung cancer vaccination?

Cancer care as a human right in low-income countries

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma